Novartis to wait for 180 days before selling itsFDA-approved biosimilar Enbrel: US court
The US Food and Drug Administration on Tuesday approved Novartis’s Erelzi as a biosimilarof Amgen’s Enbrel, which is a drug for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and other diseases. The Swiss based pharmaceutical company tried to sell its newly approved drug for $4.7 billion in yearly revenue, but sale was prevented by the US court.
The court wants Novartis to wait until 180 days from the approval to sell its biosimilar. The wait could postpone sales of Erelziuntil March next year. The company is planning to introduce the drug in the US market. This may affect Amgen, which has patent protection for its drug till 2029. Novartis’s first biosimilar was Zarxio. Novartis had to engage in a court battle with Amgen last year to get its approval.
Biosimilars copy biological products made inside living cells. Novartis is investing millions of dollars in the manufacturing of biosimilars in Austria and France. This way, the company provides affordable drugs copied from branded drugs. The drug-maker wants to attract insurers, healthcare systems and governments by offering cheaper drugs.
Erelzi is supposed to receive immense popularity for being a biosimilar of 2014’s world's fifth-biggest selling medicine. The European Medicines Agency is considering Novartis’s application that seeks approval for its biosimilar in the European markets. The US has approved the drug already, but before Novartis starts selling its copy drug, it should give 180-day-long notice to Amgen.
In the US, Erelzi is approved as more of a biosimilar than an interchangeable product. If a drug is approved as interchangeable product that indicates the drug approved has potential to generate results similar to the original drug. Biosimilar status for Erelzi indicates that the drug is very much similar to Enbrel and has no clinical differences.
The process of charging an electric car takes much longer than the conventional process of refueling vehicles with gasoline.
Following Hurricane Irma, normal operations at PortMiami, Fort Lauderdale's Port Everglades and Port Canaveral quickly resumed, but major cruise lines are facing months of disruptions to routes including stoppages at Eastern Caribbean islands that
Following an unanticipated upturn in economic activity in September, the eurozone economy is widely expected to be on track for the best quarter since 2015.
Elon Musk-led electric carmaker Tesla Motors has confirmed that it will discontinue its cheapest version of its Model S e-car, the rear-wheel-drive S60, on coming Sunday.
Motorola’s parent firm Lenovo recently announced the launch of the Moto G5S and G5S Plus smartphones in several markets. The company will shortly share its plan for worldwide launch.
Luxury vehicle maker Volvo has just introduced the 2018 XC40, the company’s latest SUV that looks forward to compete with the Porsche Macan or Range Rover Evoque.